{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:00Z","timestamp":1790678580307,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T00:00:00Z","timestamp":1357603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s11899-012-0152-z","type":"journal-article","created":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T10:31:57Z","timestamp":1357554717000},"page":"28-36","source":"Crossref","is-referenced-by-count":50,"title":["Role of Epigenetics in Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"8","author":[{"given":"Katerina","family":"Machova Polakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Koblihova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Stopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,8]]},"reference":[{"key":"152_CR1","first-page":"1497","volume":"142","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;142:1497.","journal-title":"Science"},{"key":"152_CR2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u201393.","journal-title":"Nature"},{"key":"152_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u201366.","journal-title":"Nat Med"},{"key":"152_CR4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"152_CR5","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"152_CR6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074\u201380.","journal-title":"Science"},{"key":"152_CR7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1126\/science.1063051","volume":"293","author":"M Matzke","year":"2001","unstructured":"Matzke M, Matzke AJ, Kooter JM. RNA: guiding gene silencing. Science. 2001;293:1080\u201383.","journal-title":"Science"},{"key":"152_CR8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/978-1-4419-8216-2_2","volume":"711","author":"C Bonifer","year":"2011","unstructured":"Bonifer C, Cockerill PN. Chromatin mechanisms regulating gene expression in health and disease. Adv Exp Med Biol. 2011;711:12\u201325.","journal-title":"Adv Exp Med Biol"},{"key":"152_CR9","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V94.7.2452.419k23_2452_2460","volume":"94","author":"FA Asimakopoulos","year":"1999","unstructured":"Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 1999;94:2452\u201360.","journal-title":"Blood"},{"key":"152_CR10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood.V93.6.2075.406k29_2075_2080","volume":"93","author":"JP Issa","year":"1999","unstructured":"Issa JP, Kantarjian H, Mohan A, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999;93:2075\u201380.","journal-title":"Blood"},{"key":"152_CR11","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood.V90.12.4918","volume":"90","author":"D Ben-Yehuda","year":"1997","unstructured":"Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood. 1997;90:4918\u201323.","journal-title":"Blood"},{"key":"152_CR12","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1182\/blood.V95.9.2990.009k08_2990_2992","volume":"95","author":"TT Nguyen","year":"2000","unstructured":"Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95:2990\u201392.","journal-title":"Blood"},{"key":"152_CR13","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","volume":"6","author":"J Jelinek","year":"2011","unstructured":"\u2022 Jelinek J, Gharibyan V, Estecio MR, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6:e22110. This report comprehensively describes aberrant DNA methylation of selected genes in CML.","journal-title":"PLoS One"},{"key":"152_CR14","first-page":"6931","volume":"61","author":"B Sun","year":"2001","unstructured":"Sun B, Jiang G, Zaydan MA, et al. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors. Cancer Res. 2001;61:6931\u201337.","journal-title":"Cancer Res"},{"key":"152_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/10428199809059242","volume":"32","author":"T Uchida","year":"1998","unstructured":"Uchida T, Kinoshita T, Hotta T, Murate T. High-risk myelodysplastic syndromes and hypermethylation of the p15Ink4B gene. Leuk Lymphoma. 1998;32:9\u201318.","journal-title":"Leuk Lymphoma"},{"key":"152_CR16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1365-2141.2001.02496.x","volume":"112","author":"HF Tien","year":"2001","unstructured":"Tien HF, Tang JH, Tsay W, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148\u201354.","journal-title":"Br J Haematol"},{"key":"152_CR17","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood.V95.6.1942","volume":"95","author":"IH Wong","year":"2000","unstructured":"Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942\u201349.","journal-title":"Blood"},{"key":"152_CR18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/leu.2010.41","volume":"24","author":"S Deneberg","year":"2010","unstructured":"Deneberg S, Gr\u00f6vdal M, Karimi M, et al. Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia. 2010;24:932\u201341.","journal-title":"Leukemia"},{"key":"152_CR19","doi-asserted-by":"crossref","first-page":"e12197","DOI":"10.1371\/journal.pone.0012197","volume":"5","author":"S Alvarez","year":"2010","unstructured":"Alvarez S, Suela J, Valencia A, et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One. 2010;5:e12197.","journal-title":"PLoS One"},{"key":"152_CR20","first-page":"837","volume":"57","author":"JG Herman","year":"1997","unstructured":"Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837\u201341.","journal-title":"Cancer Res"},{"key":"152_CR21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","volume":"109","author":"Y Oki","year":"2007","unstructured":"Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109:899\u2013906.","journal-title":"Cancer"},{"key":"152_CR22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3892\/ol.2011.419","volume":"3","author":"E Uehara","year":"2012","unstructured":"Uehara E, Takeuchi S, Yang Y, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett. 2012;3:190\u201392.","journal-title":"Oncol Lett"},{"key":"152_CR23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.leukres.2009.01.003","volume":"33","author":"A Avramouli","year":"2009","unstructured":"Avramouli A, Tsochas S, Mandala E, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33:1130\u201332.","journal-title":"Leuk Res"},{"key":"152_CR24","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/sj.onc.1207313","volume":"23","author":"PG Murray","year":"2004","unstructured":"Murray PG, Qiu GH, Fu L, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene. 2004;23:1326\u201331.","journal-title":"Oncogene"},{"key":"152_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1476-4598-9-44","volume":"9","author":"T Dunwell","year":"2010","unstructured":"Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer. 2010;9:44.","journal-title":"Mol Cancer"},{"key":"152_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2008.01178.x","volume":"82","author":"J Qian","year":"2009","unstructured":"Qian J, Wang YL, Lin J, et al. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol. 2009;82:119\u201323.","journal-title":"Eur J Haematol"},{"key":"152_CR27","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V77.11.2431.2431","volume":"77","author":"BD Nelkin","year":"1991","unstructured":"Nelkin BD, Przepiorka D, Burke PJ, et al. Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia. Blood. 1991;77:2431\u201334.","journal-title":"Blood"},{"key":"152_CR28","first-page":"1678","volume":"57","author":"JP Issa","year":"1997","unstructured":"Issa JP, Zehnbauer BA, Kaufmann SH, et al. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 1997;57:1678\u201381.","journal-title":"Cancer Res"},{"key":"152_CR29","first-page":"973","volume":"56","author":"JP Issa","year":"1996","unstructured":"Issa JP, Zehnbauer BA, Civin CI, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996;56:973\u201377.","journal-title":"Cancer Res"},{"key":"152_CR30","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-07-0919","volume":"13","author":"G Strathdee","year":"2007","unstructured":"Strathdee G, Holyoake TL, Sim A, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res. 2007;13:5048\u201355.","journal-title":"Clin Cancer Res"},{"key":"152_CR31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-29-54","volume":"29","author":"YL Wang","year":"2010","unstructured":"Wang YL, Qian J, Lin J, et al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res. 2010;29:54.","journal-title":"J Exp Clin Cancer Res"},{"key":"152_CR32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332.","journal-title":"Lancet Oncol"},{"key":"152_CR33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2012.09193.x","volume":"158","author":"B Scholz","year":"2012","unstructured":"Scholz B, Marschalek R. Epigenetics and blood disorders. Br J Haematol. 2012;158:307\u201322. doi: 10.1111\/j.1365-2141.2012.09193.x .","journal-title":"Br J Haematol"},{"key":"152_CR34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522\u201328.","journal-title":"Cancer"},{"key":"152_CR35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JP Issa","year":"2004","unstructured":"Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635\u201340.","journal-title":"Blood"},{"key":"152_CR36","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","volume":"23","author":"JP Issa","year":"2005","unstructured":"Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948\u201356.","journal-title":"J Clin Oncol"},{"key":"152_CR37","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","volume":"1","author":"C Arce","year":"2006","unstructured":"Arce C, P\u00e9rez-Plasencia C, Gonz\u00e1lez-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006;1:e98.","journal-title":"PLoS One"},{"key":"152_CR38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-010-1090-2","volume":"90","author":"M Candelaria","year":"2011","unstructured":"Candelaria M, Herrera A, Labardini J, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Ann Hematol. 2011;90:379\u201387.","journal-title":"Ann Hematol"},{"key":"152_CR39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2012.01.005","volume":"12","author":"E Cervera","year":"2012","unstructured":"Cervera E, Candelaria M, L\u00f3pez-Navarro O, et al. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012;12:207\u201312.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"152_CR40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature01411","volume":"421","author":"G Felsenfeld","year":"2003","unstructured":"Felsenfeld G, Groudine M. Controlling the double helix. Nature. 2003;421:448\u201353.","journal-title":"Nature"},{"key":"152_CR41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev.biochem.76.052705.162114","volume":"76","author":"MD Shahbazian","year":"2007","unstructured":"Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75\u2013100.","journal-title":"Annu Rev Biochem"},{"key":"152_CR42","doi-asserted-by":"crossref","unstructured":"Gronbaek K, Muller-Tidow C, Perini G, et al. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica. 2012 Apr 4.","DOI":"10.3324\/haematol.2011.058305"},{"key":"152_CR43","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420\u201332.","journal-title":"Oncogene"},{"key":"152_CR44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"152_CR45","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1007\/s10637-010-9590-4","volume":"28","author":"S Mithraprabhu","year":"2010","unstructured":"Mithraprabhu S, Grigoriadis G, Khong T, Spencer A. Deactylase inhibition in myeloproliferative neoplasms. Investig New Drugs. 2010;28 Suppl 1:S50\u20137.","journal-title":"Investig New Drugs"},{"key":"152_CR46","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247\u201352.","journal-title":"Oncologist"},{"key":"152_CR47","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","volume":"101","author":"R Nimmanapalli","year":"2003","unstructured":"Nimmanapalli R, Fuino L, Stobaugh C, et al. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood. 2003;101:3236\u201339.","journal-title":"Blood"},{"key":"152_CR48","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","volume":"12","author":"W Fiskus","year":"2006","unstructured":"Fiskus W, Pranpat M, Balasis M, et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006;12:5869\u201378.","journal-title":"Clin Cancer Res"},{"key":"152_CR49","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280:26729\u2013734.","journal-title":"J Biol Chem"},{"key":"152_CR50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4161\/rna.8.3.14333","volume":"8","author":"TB Hansen","year":"2011","unstructured":"Hansen TB, Kjems J, Bramsen JB. Enhnacing miRNA annotation confidence in miRBase by continuous cross dataset analysis. RNA Biol. 2011;8:378\u201383.","journal-title":"RNA Biol"},{"key":"152_CR51","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1158\/1541-7786.MCR-08-0167","volume":"6","author":"X Agirre","year":"2008","unstructured":"Agirre X, Jim\u00e9nez-Velasco A, Jos\u00e9-En\u00e9riz ES, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6:1830\u201340.","journal-title":"Mol Cancer Res"},{"key":"152_CR52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","volume":"95","author":"S Flamant","year":"2010","unstructured":"Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95:1325\u201333.","journal-title":"Haematologica"},{"key":"152_CR53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-4598-10-41","volume":"10","author":"K Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","unstructured":"\u2022 Machov\u00e1 Pol\u00e1kov\u00e1 K, Lopotov\u00e1 T, Klamov\u00e1 H, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41. First complex study about microRNA expression profiles with clinically-defined CML stages or therapeutic responses to imatinib and in silico prediction of microRNA targets underlying their importance in CML.","journal-title":"Mol Cancer"},{"key":"152_CR54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-8-69","volume":"8","author":"ES Jos\u00e9-En\u00e9riz","year":"2009","unstructured":"\u2022 Jos\u00e9-En\u00e9riz ES, Rom\u00e1n-G\u00f3mez J, Jim\u00e9nez-Velaso A, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69. First report about microRNAs that are associated with imatinib resistant patients with CML.","journal-title":"Mol Cancer"},{"key":"152_CR55","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1182\/blood-2006-09-045104","volume":"109","author":"L Venturini","year":"2007","unstructured":"Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-19-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109:4399\u2013405.","journal-title":"Blood"},{"key":"152_CR56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.leukres.2011.08.023","volume":"36","author":"V Scholl","year":"2012","unstructured":"Scholl V, Hassan R, Zalcberg IR. miRNA-451: A putative predictor marker of Imatinib therapy response in chronic myeloid leukemia. Leuk Res. 2012;36:119\u201321.","journal-title":"Leuk Res"},{"key":"152_CR57","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","volume":"19","author":"A Burchert","year":"2005","unstructured":"Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase\/Akt\/mTor activation regulates resistance development. Leukemia. 2005;19:1774\u201382.","journal-title":"Leukemia"},{"key":"152_CR58","doi-asserted-by":"crossref","first-page":"e35501","DOI":"10.1371\/journal.pone.0035501","volume":"7","author":"OH Rokah","year":"2012","unstructured":"Rokah OH, Granot G, Ovcharenko A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7:e35501.","journal-title":"PLoS One"},{"key":"152_CR59","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12079-011-0139-x","volume":"5","author":"S Suresh","year":"2011","unstructured":"Suresh S, McCallum L, Lu W, et al. MicroRNAs 130a\/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J Cell Commun Signal. 2011;5:183\u201391.","journal-title":"J Cell Commun Signal"},{"key":"152_CR60","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2007-08-105072","volume":"111","author":"MR Lidonnici","year":"2008","unstructured":"Lidonnici MR, Corradini F, Waldron T. Requirement of c-Myb for p210BCR\/ABL-dependent transformation of hematopoietic progenitors and leukemogenesis. Blood. 2008;111:4771\u201379.","journal-title":"Blood"},{"key":"152_CR61","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cell.2010.01.007","volume":"140","author":"AM Eiring","year":"2010","unstructured":"Eiring AM, Harb JG, Neviani P, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140:652\u201365.","journal-title":"Cell"},{"key":"152_CR62","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccr.2008.04.018","volume":"13","author":"MJ Bueno","year":"2008","unstructured":"Bueno MJ, Castro IP. G\u00f3mez de Cedr\u00f3n M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496\u2013506.","journal-title":"Cancer Cell"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0152-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-012-0152-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-012-0152-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:27:40Z","timestamp":1595204860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-012-0152-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,8]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1007\/s11899-012-0152-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,8]]}}}